Crimean-Congo hemorrhagic fever virus (CCHFV) causes severe human disease. The CCHFV medium RNA encodes a polyprotein which is proteolytically processed to yield the glycoprotein precursors PreGn and PreGc, followed by structural glycoproteins Gn and Gc. Subtilisin kexin isozyme-1/site-1 protease (SKI-1/S1P) plays a central role in Gn processing. Here we show that CCHFV-infected cells deficient in SKI-1/S1P produce no infectious virus, although PreGn and PreGc accumulated normally in the Golgi apparatus, the site of virus assembly. Only nucleoprotein-containing particles which lacked virus glycoproteins (Gn/Gc or PreGn/PreGc) were secreted. Complementation of SKI-1/S1P-deficient cells with a SKI-1/S1P expression vector restored release of infectious virus (>10 6 PFU/ml), confirming that SKI-1/S1P processing is required for incorporation of viral glycoproteins. SKI-1/S1P may represent a promising antiviral target.
Interestingly, SKI-1/S1P was also shown to cleave the glycoprotein precursor (GPC) of two arenaviruses, Lassa virus (13) and lymphocytic choriomeningitis virus (3) .
Proteolytic processing of viral glycoproteins is typically required for their fusogenic activity. However, lack of endoproteolysis of viral glycoproteins does not necessarily correlate with reduced infectivity. For instance, Ebola viruses displaying on their surface a mutant glycoprotein defective for furin cleavage replicate in cell culture (16) and in a nonhuman primate model (17) identically to virions displaying the wildtype cleaved glycoprotein. Here the biological significance of CCHFV PreGn conversion to Gn by SKI-1/S1P and its importance for virus infectivity were examined.
CCHFV growth in CHO-derived cells is independent of S2P activity. Cells deficient in SKI-1/S1P or S2P protease activity have been generated previously (8, 9, 19) . Both SKI-1/S1P and S2P function in the normal cellular environment in a coordinated manner such that knockout of either protease produces similar defects in the proteolytic release of host cell transcription factors from the Golgi apparatus membranes (10, 18, 20, 24) . These include the sterol-regulated element binding proteins (SREBPs) and activating transcription factor 6 (ATF6), which regulate cholesterol synthesis and unfolding protein response, respectively (20, 28) . For this reason, S2P-deficient cells were included to serve as a control for the general effect of disruption of proteolytic release of host cell transcription factors from the Golgi apparatus membranes. Following infection with CCHFV, cells were stained for CCHFV antigens by indirect immunofluorescence assay (IFA). Both cell lines displayed CCHFV antigen-positive cells at 24 h postinfection (hpi), indicating that they are susceptible to CCHFV infection (Fig. 2) . Examination of cell monolayers at 48 hpi and up to 5 days later (data not shown) showed no marked increase in the number of infected cells in cells lacking SKI-1/S1P activity, in contrast to results with S2P-deficient cells, where a substantial increase in virus antigen-positive cells was observed. These data indicate that while both cell lines are equally susceptible to initial CCHFV infection, release of infectious virus and further virus spread were inhibited in the SKI-1/S1P-deficient cells. The absence of virus growth defect in S2P-deficient cells indicates that the pleiotropic effect of SKI-1/S1P activity on host cell gene transcription was unlikely responsible for the virus lack of growth in the absence of SKI-1/S1P. Previously we had demonstrated that SKI-1/S1P-deficient cells do not produce any mature Gn (37 kDa) (27) . Taken together, these data show that the processing of PreGn to Gn is likely required to generate infectious CCHFV.
SKI-1/S1P is critical for the release of infectious virus. If SKI-1/S1P endoprotease activity was essential for CCHFV growth, then complementation of SKI-1/S1P-deficient cells with SKI-1/S1P should restore infectious virus release. Therefore, SKI-1/S1P-deficient cells were transiently transfected with a SKI-1 expression vector (or a control vector) by electroporation. Twenty-four hours later, transfected cells were infected with CCHFV, and viral antigen synthesis was moni-FIG. 2. CCHFV growth in the absence (Ϫ) of SKI-1/S1P or S2P. SRD12B cells (top, SKI-1/S1PϪ) or M19 cells (bottom, S2PϪ) were infected with CCHFV strain IbAr10200 at a multiplicity of infection of 0.5. Cells were fixed with 4% paraformaldehyde at the indicated times postinfection and irradiated with 2 ϫ 10 6 rads. Fixed cells were permeabilized with 0.5% Triton X-100 and processed by IFA with CCHFV hyperimmune mouse ascitic fluid developed against CCHFV IbAr10200, as described earlier (22) , and anti-mouse Alexa 594 antibody (Invitrogen). Images were acquired with a 20ϫ objective. The first proteolytic products are expected to occur cotranslationally or rapidly after the synthesis of the polyprotein. PreGn (140 kDa), NSm (15 kDa), and PreGc (85 kDa) are the results of these initial processing events. SKI-1/S1P and PreGc convertase will then cleave (indicated by arrows) PreGn and PreGc in the early secretory pathway. The PreGc cleavage also occurs early in the secretory pathway but the cognate protease (?) remains unidentified. (C) The activity of SKI-1/S1P and the PreGc convertase generates a nonstructural mucin-like GP38 protein of either 160 or 85 kDa, and the structural glycoproteins Gn (37 kDa) and Gc (75 kDa). (D) The mucin-like GP38 is further cleaved (arrow) by a furin-like protease in the late secretory pathway. (E) Furin-like enzyme cleavage results in production of a GP38 glycoprotein (38 kDa) and a mucin-like protein of unknown mass (? kDa).
tored by IFA. At 24 hpi, no marked difference in the numbers of infected cells was observed in the presence or absence of SKI-1/S1P (Fig. 3A) . However, cells transfected with the SKI-1/S1P expression plasmid showed a considerable increase in CCHFV-infected cells by 48 hpi, whereas no increase was observed in cells transfected with an empty vector. These data indicated that both S1P/SKI-1-expressing and nonexpressing cells were susceptible and supported CCHFV initial replication and the likelihood that S1P/SKI-1 was required for release of infectious virus and further virus spread. To examine whether infectious virus was released from these cells, the clarified cell supernatants were collected and virus titers determined by plaque assay. No infectious virus was recovered from cells lacking SKI-1/S1P (Fig. 3B) . In contrast, SKI-1/S1P-expressing cells produced high virus titers, with a peak value of 8.8 ϫ 10 6 PFU/ml, 48 h after the initial infection. These results clearly indicated that SKI-1/S1P was strictly required for infectious CCHFV production.
Secretion of low levels of glycoprotein-deficient viral particles in the absence of SKI-1/S1P. Analysis of other viral systems has demonstrated that disruption of viral glycoprotein cleavage can lead to the formation of virus particles decorated with uncleaved glycoprotein precursors on their surface (4, 5, 16, 25, 29) . This situation applies to viral glycoproteins incom- FIG. 3 . Production of infectious CCHFV from SKI-1/S1P-deficient cells can be rescued by plasmid-expressed SKI-1/S1P. (A) SKI-1/S1P-deficient cells (SRD12B cells) were transiently transfected with control empty vector (top, ϪSKI-1/S1P) or with SKI-1/S1P-containing vector (bottom, ϩSKI-1/S1P) by use of a Nucleofector II electroporator, the H-014 program, and cell line Nucleofector solution T (Amaxa, Gaithersburg, MD). These transfected cells were infected 24 hpi and processed at the indicated times postinfection as described in the legend for Fig. 2 . No obvious cytopathic effect was observed in the presence or absence of SKI-1/S1P (data not shown). (B) Infections were set up as described above. Infected cell supernatants were collected, clarified, and frozen in liquid nitrogen at the indicated times for subsequent titration by plaque assay on SW13 cell monolayers (22) . Red bars indicate viral titers from ϪSKI-1/S1P-transfected and blue bars from ϩSKI-1/S1P-transfected cell supernatants.
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FIG. 4 . Glycoprotein-deficient viral particles are released in the infected cell supernatant of SKI-1/S1P-deficient cells. SRD12B cells stably expressing SKI-1/S1P were produced by transfection of the pIR-SKI-1/S1P vector with Lipofectamine 2000. Two days after transfection, cells were placed in Dulbecco's modified Eagle's medium-F-12 medium supplemented with 5% lipoprotein-deficient fetal bovine serum and penicillinstreptomycin for 14 days to select cells stably expressing SKI-1/S1P. The cell pools growing in the absence of exogenous cholesterol were used in all experiments. (A) SKI-1/S1P-deficient cells (ϪSKI/S1P) or SKI-1/S1P-deficient cells stably expressing SKI-1/S1P (ϩSKI-1/S1P) were infected with a multiplicity of infection (MOI) of 5. Twenty-four hpi, cells were pulsed with 100 Ci/ml of [ 35 S]Cys for 30 min and chased for the indicated number of hours, as described previously (22) . Triton X-100 was added to a concentration of 1% to cell supernatants prior to the immunoprecipitation with anti-N (5G2) MAb and protein A Sepharose (Amersham). Cell monolayers were solubilized with radioimmunoprecipitation assay buffer and immunoprecipitations carried out as described previously (22) . All immunoprecipitated proteins were resolved with a NuPAGE gel system (3 to 8% bis-Tris gels) under reducing conditions. Protein bands were detected using phosphor screens and image digitized and quantitated using a Storm imager (GE Healthcare Biosciences) and ImageQuant software (GE Healthcare Biosciences). At the time of the pulse, we estimated by IFA that ϳ15% of the SKI-1/S1P-deficient cells were infected, compared to ϳ40% for cells expressing SKI-1/S1P (data not shown). (B) Confluent 175-cm 2 flasks of SRD12B cells or SRD12B cells stably expressing SKI-1 were infected with CCHFV with an MOI of 5. Uninfected (Ϫ) and infected (ϩ) cell supernatants were changed 24 h after the infection and collected at 48 hpi and viral particles purified as essentially as described previously (1) . Purified viral pellets were solubilized in 100 l of 2ϫ NuPAGE sample buffer and gamma irradiated with 2 ϫ 10 6 rads prior to electrophoresis. A portion (20 l) of the reduced samples was analyzed by Western blotting with chemiluminescence to detect CCHFV structural proteins N (9D5 MAb), Gn (Gn ectodomain polyclonal antibody), and Gc (11E7 MAb). The values at right are markers in kilodaltons. (C) SKI-1/S1P-deficient cells were infected and processed by IFA with antibodies 7F5 (PreGn/GP38) or 11E7 (PreGc/Gc) and Giantin (Golgi) from Covance (Berkeley, CA) 7 hpi. The green signal (anti-mouse Alexa 488) is specific for PreGn (top) or PreGc/Gc (bottom) and red (anti-rabbit Alexa 594) for Giantin (Golgi). Red and green digital images were overlaid (merged) to emphasize the colocalization of PreGn and PreGc/Gc with the cis and median Golgi cisternae marker. Images were acquired with a 100ϫ objective.
pletely cleaved by furin-like convertases or to furin-resistant mutants. In contrast, only correctly SKI-1/S1P-processed mature glycoproteins (GP1 and GP2) are incorporated into arenavirus viral particles (12, 13) . In order to determine if any viral proteins were secreted from CCHFV-infected cells, we analyzed the cell lysates and supernatants of infected SKI-1/ S1P-deficient cells by pulse-chase and immunoprecipitation analyses in the presence or absence of SKI-1/S1P (Fig. 4A) . Three to four times less labeled N protein was detected in lysates of SKI-1/S1P-deficient cells than in SKI-1/S1P-expressing cells at all time points examined (Fig. 4A) . These findings are consistent with earlier results which demonstrated a lack of CCHFV production and spread in cells lacking SKI-1/S1P (Fig.  3) . Nucleoprotein secretion into the supernatant increased over time in the presence or absence of SKI-1/S1P (Fig. 4A) . However, five or eight times more N protein was secreted after 1 or 3 h chase, respectively, when SKI-1/S1P-expressing cells were compared with nonexpressing cells. These data indicated that a time-dependent increase in N secretion was observed in the absence of SKI-1/S1P activity but that the amount of N secreted was significantly smaller. As expected, and confirmed previously (27) , uncleaved PreGn was detectable in the SKI-1/S1P-deficient cell lysates but not in supernatants (data not shown).
The preceding data suggested that noninfectious N-containing viral particles are produced even in the absence of PreGn processing. To examine this, CCHFV-infected cell supernatants were pelleted through a sucrose cushion to partially purify any virus particles present, and viral pellets were examined for the presence of N, Gn, and Gc by Western blotting. N protein was detected in viral pellets even in the absence of SKI-1/S1P, albeit to a much lower level than in SKI-1/S1P-expressing cells (Fig. 4B) . Despite good detection sensitivity, Gn (37 kDa), Gn dimers (70 kDa) (1), and Gc were observed only in SKI-1/S1P-expressing cells. In addition, no virus glycoprotein precursors (PreGn or PreGc) were detected in any of the virus pellets. These results strongly suggest that in the absence of SKI-1/S1P activity, low levels of CCHFV particles are produced, and that these are essentially naked nucleocapsid cores containing no or undetectable levels of mature Gn, Gc, or glycoprotein precursor forms.
PreGn and PreGc/Gc are localized in the Golgi apparatus. A hallmark of members of the family Bunyaviridae is the targeting of their surface glycoproteins to the Golgi apparatus, where most viral assembly takes place. To determine if PreGn processing was required for the proper Golgi apparatus localization of the glycoproteins, we analyzed CCHFV-infected cells deficient in S1P/SKI-1 or transfected HeLa cells expressing a S1P/SKI-1 cleavage-resistant M polyprotein mutant (IRLL 519 ) (27) . IFA of these cells using PreGn/GP38-or PreGc/Gc-specific monoclonal antibodies (MAbs) showed that these proteins colocalized with a cis and median Golgi cisternae marker (Giantin) in both CCHFV-infected (Fig. 4C ) and transfected (data not shown) cells. Since both PreGn and PreGc/Gc were localized in the Golgi apparatus in the absence of mature 37-kDa Gn, we concluded that glycoprotein trafficking was normal even in the absence of S1P/SKI-1 activity.
The fact that glycoprotein precursors were localized in the Golgi apparatus, the site of CCHFV assembly, but failed to be incorporated into particles suggests a selective mechanism for the incorporation of mature Gn and Gc into virions. An analogous situation has been reported for the GPCs of Lassa virus and lymphocytic choriomeningitis virus. The supernatants of SKI-1/S1P-deficient cells infected with these arenaviruses also contained a low abundance of N-containing noninfectious particles deficient in envelope GPC or mature cleavage products (GP1 and GP2) (12, 13) . In contrast, it has been demonstrated for numerous other viruses that blockage of furin processing of glycoprotein precursors does not inhibit formation of virus particles (4, 5, 16, 29) , suggesting that blockage of virion formation may be limited to glycoproteins cleaved by SKI-1/S1P. While unlikely, we cannot rule out that SKI-1/S1P could impact CCHFV budding in a manner unrelated to its protease activity.
SKI-1/S1P motifs can be identified in the deduced amino acid sequences of the glycoprotein precursors of not only all CCHFV strains sequenced to date but also Dugbe and Hazara viruses, the only other nairoviruses for which sequences are available. Therefore, SKI-1/S1P processing of PreGn is likely a shared feature of members of the genus Nairovirus and infectivity of these viruses may also be dependent on SKI-1/S1P. In contrast, the absence of such predicted sites in other genera of the family Bunyaviridae suggests that their growth is independent of SKI-1/S1P activity. In agreement, we observed that SKI-1/S1P-deficient cells are permissive to Rift Valley fever virus, a member of the genus Phlebovirus (data not shown).
CCHF is a rapidly progressing acute disease associated with high mortality. No vaccine is licensed currently, and limited antiviral therapeutic options exist. The strong dependence of CCHFV (and the hemorrhagic fever-associated arenaviruses) on SKI-1/S1P cleavage for production of infectious virus particles suggests that the development of SKI-1/S1P small-molecule inhibitors may represent a promising avenue for antiviral development.
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